Literature DB >> 1446861

Plasma polyunsaturated fatty acid pattern in active inflammatory bowel disease.

M Esteve-Comas1, M Ramírez, F Fernández-Bañares, A Abad-Lacruz, A Gil, E Cabré, F González-Huix, J Moreno, P Humbert, M Guilera.   

Abstract

Plasma fatty acid patterns were assessed by gas liquid chromatography in 73 patients with active inflammatory bowel disease and 107 healthy controls. The influence of the disease activity on fatty acid profile was also investigated. Plasma fatty acid patterns in patients with ulcerative colitis and Crohn's disease were similar. Plasma C18:3n3 and C22:6n3 were significantly higher in active ulcerative colitis (p = 0.0143 and p < 0.00001 respectively) and in Crohn's disease (p < 0.00001 for both) than in controls, whereas C20:3n6 was significantly lower in patients than in controls, both in ulcerative colitis (p = 0.0001) and in Crohn's disease (p = 0.0041). In more severe disease, plasma polyunsaturated fatty acid concentrations fell with a significant stepwise decrease in the desaturation index (p = 0.0031 in ulcerative colitis and p = 0.0355 in Crohn's disease). Even in patients with severe disease, however, plasma n3 fatty acids (C18:3n3 and C22:6n3) never fell below those of healthy controls. These findings suggest that in active inflammatory bowel disease, an increased biosynthesis might coexist with an increased consumption of polyunsaturated fatty acids. These observations may be of relevance in the pathogenesis of the disease as polyunsaturated fatty acids are involved in tissue eicosanoid synthesis and cellular membrane function, including that of immunocompetent cells. These results also question the rationale of using n3 polyunsaturated fatty acids in the treatment of inflammatory bowel disease.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1446861      PMCID: PMC1379605          DOI: 10.1136/gut.33.10.1365

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  40 in total

1.  Cortisone in ulcerative colitis; final report on a therapeutic trial.

Authors:  S C TRUELOVE; L J WITTS
Journal:  Br Med J       Date:  1955-10-29

Review 2.  Prostaglandins and thromboxanes.

Authors:  B Samuelsson; M Goldyne; E Granström; M Hamberg; S Hammarström; C Malmsten
Journal:  Annu Rev Biochem       Date:  1978       Impact factor: 23.643

3.  Analysis of fatty acids from human lipids by gas chromatography.

Authors:  G J Haan; S van der Heide; B G Wolthers
Journal:  J Chromatogr       Date:  1979-03-01

4.  a-Linolenic acid as a regulator of the metabolism of arachidonic acid: dietary implications of the ratio, n-6:n-3 fatty acids.

Authors:  P Budowski; M A Crawford
Journal:  Proc Nutr Soc       Date:  1985-07       Impact factor: 6.297

5.  Increased arachidonic acid composition of phospholipids in colonic mucosa from patients with active ulcerative colitis.

Authors:  T Nishida; H Miwa; A Shigematsu; M Yamamoto; M Iida; M Fujishima
Journal:  Gut       Date:  1987-08       Impact factor: 23.059

6.  Effect of dietary enrichment with eicosapentaenoic and docosahexaenoic acids on in vitro neutrophil and monocyte leukotriene generation and neutrophil function.

Authors:  T H Lee; R L Hoover; J D Williams; R I Sperling; J Ravalese; B W Spur; D R Robinson; E J Corey; R A Lewis; K F Austen
Journal:  N Engl J Med       Date:  1985-05-09       Impact factor: 91.245

7.  The composition of food consumed by Greenland Eskimos.

Authors:  H O Bang; J Dyerberg; N Hjøorne
Journal:  Acta Med Scand       Date:  1976

8.  Plasma fatty acid composition in patients with ileal dysfunction.

Authors:  M A Färkkilä; R S Tilvis; T A Miettinen
Journal:  Scand J Gastroenterol       Date:  1987-05       Impact factor: 2.423

9.  In vivo profiles of eicosanoids in ulcerative colitis, Crohn's colitis, and Clostridium difficile colitis.

Authors:  K Lauritsen; L S Laursen; K Bukhave; J Rask-Madsen
Journal:  Gastroenterology       Date:  1988-07       Impact factor: 22.682

10.  Supplementation with n-3 fatty acids from fish oil in chronic inflammatory bowel disease--a randomized, placebo-controlled, double-blind cross-over trial.

Authors:  R Lorenz; P C Weber; P Szimnau; W Heldwein; T Strasser; K Loeschke
Journal:  J Intern Med Suppl       Date:  1989
View more
  24 in total

1.  Serum n3 polyunsaturated fatty acids are depleted in Crohn's disease.

Authors:  F Kuroki; M Iida; T Matsumoto; K Aoyagi; K Kanamoto; M Fujishima
Journal:  Dig Dis Sci       Date:  1997-06       Impact factor: 3.199

Review 2.  New insights into the role of fatty acids in the pathogenesis and resolution of inflammatory bowel disease.

Authors:  Darla R Shores; David G Binion; Bruce A Freeman; Paul R S Baker
Journal:  Inflamm Bowel Dis       Date:  2010-12-03       Impact factor: 5.325

3.  Plasma and mucosal fatty acid pattern in colectomized ulcerative colitis patients.

Authors:  M Esteve; E Navarro; J Klaassen; A Abad-Lacruz; F González-Huix; E Cabré; E Ramos; E Condom; F Fernández-Bañares; C Pastor; P Humbert; J Martí-Ragué; M A Gassull
Journal:  Dig Dis Sci       Date:  1998-05       Impact factor: 3.199

4.  Dietary fat intake and inflammatory bowel disease.

Authors:  M A Gassull
Journal:  Curr Gastroenterol Rep       Date:  2001-08

5.  Abnormal plasma polyunsaturated fatty acid pattern in non-active inflammatory bowel disease.

Authors:  M Esteve-Comas; M C Núñez; F Fernández-Bañares; A Abad-Lacruz; A Gil; E Cabré; F González-Huix; X Bertrán; M A Gassull
Journal:  Gut       Date:  1993-10       Impact factor: 23.059

Review 6.  Enteral nutrition as primary therapy in Crohn's disease.

Authors:  F Fernández-Bañares; E Cabré; F González-Huix; M A Gassull
Journal:  Gut       Date:  1994-01       Impact factor: 23.059

7.  Restorative proctocolectomy for ulcerative colitis: impact on lipid metabolism and adipose tissue and serum fatty acids.

Authors:  Marco Scarpa; Giovanna Romanato; Enzo Manzato; Cesare Ruffolo; Raffaella Marin; Silvia Basato; Sabina Zambon; Teresa Filosa; Silvia Zanoni; Fabio Pilon; Lino Polese; Giacomo C Sturniolo; Davide F D'Amico; Imerio Angriman
Journal:  J Gastrointest Surg       Date:  2007-10-23       Impact factor: 3.452

8.  Metabolic syndrome affects fatty acid composition of plasma lipids in obese prepubertal children.

Authors:  Mercedes Gil-Campos; Maria del Carmen Ramírez-Tortosa; Elvira Larqué; Javier Linde; Concepción M Aguilera; Ramón Cañete; Angel Gil
Journal:  Lipids       Date:  2008-07-01       Impact factor: 1.880

9.  Polymeric enteral diets as primary treatment of active Crohn's disease: a prospective steroid controlled trial.

Authors:  F González-Huix; R de León; F Fernández-Bañares; M Esteve; E Cabré; D Acero; A Abad-Lacruz; M Figa; M Guilera; R Planas
Journal:  Gut       Date:  1993-06       Impact factor: 23.059

10.  Lipid and phospholipid profile after bowel resection for Crohn's disease.

Authors:  Giovanna Romanato; Marco Scarpa; Cesare Ruffolo; Raffaella Marin; Sabina Zambon; Silvia Zanoni; Silvia Basato; Teresa Filosa; Fabio Pilon; Imerio Angriman; Enzo Manzato
Journal:  Int J Colorectal Dis       Date:  2008-07-03       Impact factor: 2.571

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.